Methods for the Automated Manufacturing of an Autologous Dendritic-Cell Immunotherapy - The author describes the development of automated equipment that uses functionally closed disposables to perform

ADVERTISEMENT

Methods for the Automated Manufacturing of an Autologous Dendritic-Cell Immunotherapy
The author describes the development of automated equipment that uses functionally closed disposables to perform cellular and ribonucleic acid processing.


BioPharm International
Volume 24, Issue 12, pp. 50-54

CONCLUSION

These prototypes demonstrated the feasibility of this automated approach. The automated equipment and the associated disposable sets or components provides a platform technology to enable commercial manufacturing of complex autologous DC immunotherapies.

Tamara T. Monesmith is a director of manufacturing and process development at Argos Therapeutics, 4233 Technology Dr., Durham, NC 27704, tel. 919.287.6300, fax 919.287.6301,
.

REFERENCES

1. J. Harris et al., Biochim. Biophys. Acta 1724 (1-2), 127–136 (2005).

2. I. Tcherepanova et al., PLoS One 1 (e1489), 1–10 (2008).

3. S.R. Bennett et al., Nature 393 (6684), 478–480 (1998).

4. J.P. Ridge, R.F. Di, and P. Matzinger, Nature 393 (6684), 474–478 (1998).

5. S.P. Schoenberger et al., Nature 393 (6684), 480–483 (1998).

6. P.T. Coates et al., Expert Rev. Mol. Med. 4 (3),1–21 (2002).

7. M.A. DeBenedette et al., J. Immunother. 34 (1), 45–57 (2011).

8. I.Y. Tcherepanova et al., BMC Mol. Biol. 9 (90), 1–13 (2008).

9. D.M. Calderhead et al., J. Immunother. 31 (8), 731-741 (2008).

10. M.A. DeBenedette et al., J. Immunol. 181 (8), 5296–5305 (2008).

11. A. Jemal et al., CA Cancer J. Clin. 60 (5), 277–300 (2010).

12. S.A. Karumanchi, J. Merchan, and V.P. Sukhatme, Curr. Opin. Nephrol. Hypertens. 11 (1), 37–42 (2002).

13. National Cancer Institute, SEER Cancer Statistics Review, 1975–2007, S.F. Altekruse et al., Eds. (NCI, Bethesda, MD, 2010).

14. K.J. Pienta and D.C. Smith, CA Cancer J. Clin. 55 (5), 300–318 (2005).



blog comments powered by Disqus

ADVERTISEMENT

ADVERTISEMENT

Lundbeck CEO Resigns Due to Code of Conduct Breach
November 24, 2014
IMS: Global Spending on Medicines to Rise 30% by 2018
November 24, 2014
Janssen Partners with Transposagen Biopharmaceuticals for CAR-T Therapies
November 24, 2014
Amgen Opens Single-Use Manufacturing Plant in Singapore
November 20, 2014
GPhA Issues Statement on Generic Drug Costs
November 20, 2014
Author Guidelines
Source: BioPharm International,
Click here